GlassScriptPhysician profile
William K Briggs
NPI 1730176884
$14,363.58
in general payments reported to CMS, 2019-2025
45 companies · $2,812 in 2025
The $2,812 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $1,602 · 2021: $1,939 · 2022: $1,907 · 2023: $2,026 · 2024: $2,275 · 2025: $2,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,113.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,745.97 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,908.07 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,505.98 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $1,494.51 | 2019-2025 | |
| Janssen Biotech, INC. | $775.81 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $772.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $381.96 | 2022-2025 | Dupixent |
| Genzyme Corporation | $368.49 | 2022-2025 | |
| Qol Medical, LLC | $312.35 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $309.13 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $303.37 | 2019-2024 | Rebyota, Cimzia |
| Celgene Corporation | $202.00 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $201.70 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $196.28 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $166.39 | 2024-2025 | Omvoh |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.